Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
55.13
-0.26 (-0.47%)
At close: Apr 2, 2026, 4:00 PM EDT
55.13
0.00 (0.00%)
After-hours: Apr 2, 2026, 4:00 PM EDT
Monopar Therapeutics Employees
As of December 31, 2024, Monopar Therapeutics had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 6 or 60.00% compared to the previous year.
Employees
16
Change (1Y)
6
Growth (1Y)
60.00%
Revenue / Employee
n/a
Profits / Employee
-$857,306
Market Cap
368.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 16 | 6 | 60.00% | 14 | 2 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 9 | 1 |
| Dec 31, 2022 | 12 | 2 | 20.00% | 11 | 1 |
| Dec 31, 2021 | 10 | 0 | - | 9 | 1 |
| Dec 31, 2020 | 10 | 3 | 42.86% | 9 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Invivyd | 122 |
| Enanta Pharmaceuticals | 120 |
| Niagen Bioscience | 117 |
| Neumora Therapeutics | 95 |
| Armata Pharmaceuticals | 60 |
| PureTech Health | 56 |
| Candel Therapeutics | 55 |
MNPR News
- 6 days ago - Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - GlobeNewsWire
- 5 months ago - Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments - GlobeNewsWire
- 5 months ago - Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 6 months ago - Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 - GlobeNewsWire
- 6 months ago - Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 6 months ago - Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients - GlobeNewsWire
- 7 months ago - Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting - GlobeNewsWire